Bellevue Group’s ResMed RMD Stock Holding History

Bellevue Group’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.8M	Sell	159,346 -1,868	-1%	-$466K	0.85%	35
2025 Q4	$38.8M	Sell	161,214 -3,620	-2%	-$926K	0.74%	31
2025 Q3	$45.1M	Sell	164,834 -968	-0.6%	-$264K	0.94%	27
2025 Q2	$42.8M	Hold	165,802	–	–	0.94%	26
2025 Q1	$37.1M	Buy	165,802 +5,009	+3%	+$1.17M	0.83%	28
2024 Q4	$36.8M	Buy	160,793 +665	+0.4%	+$160K	0.71%	32
2024 Q3	$39.1M	Buy	160,128 +4,247	+3%	+$949K	0.63%	44
2024 Q2	$29.8M	Buy	155,881 +125,490	+413%	+$25.5M	0.48%	58
2024 Q1	$6.02M	Buy	30,391 +71	+0.2%	+$13K	0.09%	94
2023 Q4	$5.22M	Sell	30,320 -46,376	-60%	-$7.13M	0.08%	94
2023 Q3	$11.3M	Sell	76,696 -21,579	-22%	-$3.9M	0.18%	87
2023 Q2	$21.5M	Hold	98,275	–	–	0.31%	74
2023 Q1	$21.5M	Hold	98,275	–	–	0.31%	77
2022 Q4	$20.5M	Buy	98,275 +13,663	+16%	+$3M	0.27%	83
2022 Q3	$18.5M	Sell	84,612 -253	-0.3%	-$57.6K	0.27%	85
2022 Q2	$17.8M	Sell	84,865 -1,484	-2%	-$316K	0.25%	91
2022 Q1	$20.9M	Sell	86,349 -141	-0.2%	-$34.1K	0.24%	92
2021 Q4	$22.5M	Sell	86,490 -1,655	-2%	-$429K	0.23%	100
2021 Q3	$23.2M	Hold	88,145	–	–	0.24%	99
2021 Q2	$21.7M	Hold	88,145	–	–	0.21%	105
2021 Q1	$17.1M	Sell	88,145 -10,830	-11%	-$2.17M	0.18%	104
2020 Q4	$21M	Buy	98,975 +21,170	+27%	+$4.22M	0.24%	97
2020 Q3	$13.3M	Hold	77,805	–	–	0.18%	101
2020 Q2	$14.9M	Sell	77,805 -700	-0.9%	-$115K	0.21%	91
2020 Q1	$11.6M	Buy	78,505 +2,695	+4%	+$429K	0.22%	77
2019 Q4	$11.7M	Buy	75,810 +21,180	+39%	+$3.05M	0.19%	84
2019 Q3	$7.38M	Buy	54,630 +2,004	+4%	+$263K	0.14%	98
2019 Q2	$6.42M	Sell	52,626 -2,041	-4%	-$226K	0.11%	102
2019 Q1	$5.68M	Sell	54,667 -725	-1%	-$74.8K	0.31%	74
2018 Q4	$6.31M	Sell	55,392 -37,800	-41%	-$4.05M	0.41%	59
2018 Q3	$10.7M	Buy	93,192 +10,992	+13%	+$1.2M	0.68%	47
2018 Q2	$8.51M	Sell	82,200 -24,800	-23%	-$2.51M	0.73%	48
2018 Q1	$10.5M	Buy	107,000 +60,000	+128%	+$5.67M	1.04%	38
2017 Q4	$3.98M	Hold	47,000	–	–	0.42%	54
2017 Q3	$3.62M	Buy	47,000 +10,900	+30%	+$834K	0.38%	61
2017 Q2	$2.81M	Buy	36,100 +28,100	+351%	+$2.01M	0.33%	66
2017 Q1	$576K	Hold	8,000	–	–	0.08%	120
2016 Q4	$496K	Hold	8,000	–	–	0.1%	111
2016 Q3	$518K	Hold	8,000	–	–	0.09%	115
2016 Q2	$506K	Hold	8,000	–	–	0.1%	111
2016 Q1	$463K	Buy	+8,000	New	+$453K	0.08%	113

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bellevue Group's RMD Position: Q1 2026 in Review

Bellevue Group reduced its ResMed (RMD) stake by 1.2% in Q1 2026, selling an estimated $466K and leaving 159,346 shares worth $35.8M. The position accounts for 0.85% of the portfolio, ranked #35.

Bellevue Group first reported a position in RMD in Q1 2016 and has held it in 41 quarters since. The position peaked at $45.1M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Bellevue Group held 159,346 shares of ResMed worth $35.8M as of Q1 2026.
Bellevue Group sold 1,868 ResMed shares in Q1 2026, an estimated $466K.
ResMed made up 0.85% of Bellevue Group's portfolio in Q1 2026, its #35 holding.
Bellevue Group first reported a position in ResMed in Q1 2016 and has held it in 41 quarters since.
Bellevue Group's ResMed position peaked at $45.1M in Q3 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.